Kumar G - Search Results

1

In vitro assessment of cytochrome P450 inhibition and induction potential of azacitidine.

Chen Y, Liu L, Laille E, Kumar G, Surapaneni S. Chen Y, et al. Among authors: kumar g. Cancer Chemother Pharmacol. 2010 Apr;65(5):995-1000. doi: 10.1007/s00280-010-1245-9. Epub 2010 Jan 30. Cancer Chemother Pharmacol. 2010. PMID: 20119716 Free PMC article.

2

Role of drug metabolism in drug discovery and development.

Kumar GN, Surapaneni S. Kumar GN, et al. Med Res Rev. 2001 Sep;21(5):397-411. doi: 10.1002/med.1016. Med Res Rev. 2001. PMID: 11579440 Review.

3

Identification of a novel in vitro metabonate from liver microsomal incubations.

Li C, Surapaneni S, Zeng Q, Marquez B, Chow D, Kumar G. Li C, et al. Among authors: kumar g. Drug Metab Dispos. 2006 Jun;34(6):901-5. doi: 10.1124/dmd.105.008367. Epub 2006 Mar 22. Drug Metab Dispos. 2006. PMID: 16554371

4

Lenalidomide: in vitro evaluation of the metabolism and assessment of cytochrome P450 inhibition and induction.

Kumar G, Lau H, Laskin O. Kumar G, et al. Cancer Chemother Pharmacol. 2009 May;63(6):1171-5. doi: 10.1007/s00280-008-0867-7. Epub 2008 Nov 23. Cancer Chemother Pharmacol. 2009. PMID: 19030860

5

In vitro metabolism of the novel, highly selective oral angiogenesis inhibitor motesanib diphosphate in preclinical species and in humans.

Li C, Kuchimanchi M, Hickman D, Poppe L, Hayashi M, Zhou Y, Subramanian R, Kumar G, Surapaneni S. Li C, et al. Among authors: kumar g. Drug Metab Dispos. 2009 Jul;37(7):1378-94. doi: 10.1124/dmd.108.025742. Epub 2009 Apr 16. Drug Metab Dispos. 2009. PMID: 19372226

6

Disposition, metabolism and mass balance of [(14)C]apremilast following oral administration.

Hoffmann M, Kumar G, Schafer P, Cedzik D, Capone L, Fong KL, Gu Z, Heller D, Feng H, Surapaneni S, Laskin O, Wu A. Hoffmann M, et al. Among authors: kumar g. Xenobiotica. 2011 Dec;41(12):1063-75. doi: 10.3109/00498254.2011.604745. Epub 2011 Aug 23. Xenobiotica. 2011. PMID: 21859393 Free PMC article. Clinical Trial.

7

Pharmacokinetics, metabolism and excretion of [(14)C]-lenalidomide following oral administration in healthy male subjects.

Chen N, Wen L, Lau H, Surapaneni S, Kumar G. Chen N, et al. Among authors: kumar g. Cancer Chemother Pharmacol. 2012 Mar;69(3):789-97. doi: 10.1007/s00280-011-1760-3. Epub 2011 Oct 29. Cancer Chemother Pharmacol. 2012. PMID: 22037879 Free PMC article. Clinical Trial.

8

Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration.

Hoffmann M, Kasserra C, Reyes J, Schafer P, Kosek J, Capone L, Parton A, Kim-Kang H, Surapaneni S, Kumar G. Hoffmann M, et al. Among authors: kumar g. Cancer Chemother Pharmacol. 2013 Feb;71(2):489-501. doi: 10.1007/s00280-012-2040-6. Epub 2012 Dec 1. Cancer Chemother Pharmacol. 2013. PMID: 23203815 Free PMC article. Clinical Trial.

9

The interactions of lenalidomide with human uptake and efflux transporters and UDP-glucuronosyltransferase 1A1: lack of potential for drug-drug interactions.

Tong Z, Yerramilli U, Surapaneni S, Kumar G. Tong Z, et al. Among authors: kumar g. Cancer Chemother Pharmacol. 2014 Apr;73(4):869-74. doi: 10.1007/s00280-014-2415-y. Epub 2014 Mar 14. Cancer Chemother Pharmacol. 2014. PMID: 24627218

10

Pomalidomide: evaluation of cytochrome P450 and transporter-mediated drug-drug interaction potential in vitro and in healthy subjects.

Kasserra C, Assaf M, Hoffmann M, Li Y, Liu L, Wang X, Kumar G, Palmisano M. Kasserra C, et al. Among authors: kumar g. J Clin Pharmacol. 2015 Feb;55(2):168-78. doi: 10.1002/jcph.384. Epub 2014 Sep 7. J Clin Pharmacol. 2015. PMID: 25159194 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,166 results

Search Page

Filters